360b / Shutterstock.com
Pharmaceutical companies including Cipla and Natco Pharma have signed a sub-licensing deal enabling them to produce a generic version of Bristol Myers Squibb’s (BMS) hepatitis C drug Daclatasvir (daklinza).
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Cipla, Natco, Emcure, Hetero, Bristol Myers Squibb, Hepatitis C, paye, daclatasvir, Greg Perry, Medicines Patent Pool, MPP, Rajeev Nannapaneni, Vik Thapar,
